非典型抗精神病药再普乐治疗精神分裂症的疗效和安全性研究  

To study the Bullock treatment of schizophrenia to the efficacy and safety

作　　者：左文华 李言禹 陈方基 

机构地区：[1]山东省莱西市市立医院精神科,266600

出　　处：《中国医疗前沿》2011年第16期11-12,共2页China Healthcare Innovation

摘　　要：目的探讨再普乐治疗精神分裂症的疗效和安全性。方法对64例大样本再普乐开放性观察性临床试验的数据进行汇总。四项研究使用再普乐的剂量为5-30mg/d,疗程为6周。采用阳性与阴性症状量表(PANSS)以及简明精神病评定量表(BPRS)评定疗效;采用副反应量表(TESS)和Simpson-Angus量表评定不良反应。结果 64例患者中,有36例符合痊愈的标准,20例显著进步,6例进步,2例无变化。结论再普乐治疗精神分裂症疗效良好,发生锥体外系副作用少,提倡临床使用再普乐治疗精神分裂症。Objective To explore the bullock treatment of schizophremia to understand the efficacy and safety.Methods 64 cases of large samples Bullock open to observation of clinical trial data summary.Four studies of the use of tacrolimus dose of 5-30mg/d,for the six-week course of treatment.Use positive and negative symptom scale（PANSS） and the brief psychiatric rating scale（BPRS） for efficacy;Using reaction scale（TESS） and the Simpson-Angus scale of adverse reactions.Results In 64 patients,36 cases with the recovery standards,20 cases of significant progress,progress in six cases,two unchanged.Conclusion Again Bullock efficacy in the treatment of schizophrenia good treatment in fewer extrapyramidal side effects,advocates of the use of tacrolimus treatment of schizophremia.

关 键 词：精神分裂症 再普乐 锥体外系 抗精神药物 疗效 安全性 

分 类 号：R749.3[医药卫生—神经病学与精神病学]